FDA Grants Priority Review to AstraZeneca’s Sonesitatug Vedotin
The FDA granted priority review to AstraZeneca’s sonesitatug vedotin for advanced gastric cancers.
The FDA granted priority review to AstraZeneca’s sonesitatug vedotin for advanced gastric cancers.